(Bold for FDA approved)
How Stelazine works• Blocks dopamine 2 receptors, reducing positive symptoms of psychosis
• Psychotic symptoms can improve within 1 week, but it may take several weeks for full effect on behavior
Notable Side Effects• Neuroleptic-induced deficit syndrome
• Akathisia
• Rash
• Priapism
• Drug-induced parkinsonism
• Tardive dyskinesia, tardive dystonia
• Risk of potentially irreversible involuntary dyskinetic movements may increase with cumulative dose and treatment duration
• Galactorrhea, amenorrhea
• Dizziness, sedation
• Dry mouth, constipation, blurred vision, urinary retention
• Decreased sweating
• Sexual dysfunction
• Hypotension
Life Threatening Side Effects• Rare neuroleptic malignant syndrome may cause hyperpyrexia, muscle rigidity, delirium, and autonomic instability with elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure
• Rare jaundice, agranulocytosis
• Rare seizures
• As a class, antipsychotics are associated with an increased risk of death and cerebrovascular events in elderly patients with dementia; not approved for treatment of dementia-related psychosis

unusual

common
Wait
• Wait
• Wait
• For drug-induced parkinsonism, add an anticholinergic agent
• Beta blockers, benzodiazepines, or serotonin 2A antagonists (e.g., mirtazapine, cyproheptadine) may reduce akathisia
• Reduce the dose
• For sedation, give at night
• Switch to an atypical antipsychotic
• Weight loss, exercise programs, and medical management for high BMIs, diabetes, dyslipidemia
• Metformin may help prevent or reverse antipsychotic-induced weight gain
• Oral: psychosis: 15–20 mg/day
Dosage Forms• Tablet 1 mg, 2 mg, 5 mg, 10 mg
• Vial 2 mg/mL (discontinued in USA)
• Concentrate 10 mg/mL (discontinued in USA)
• Should periodically reevaluate long-term usefulness in individual patients, but treatment may need to continue for many years
• Not intended to treat anxiety long-term (i.e., longer than 12 weeks)
• No
Renal Impairment• Use with caution
Hepatic Impairment• Not recommended for use
Cardiac Impairment• Dose should be lowered
• Do not use parenteral administration unless necessary
Elderly• Lower doses should be used and patient should be monitored closely
• Although conventional antipsychotics are commonly used for behavioral disturbances in dementia, no agent has been approved for treatment of elderly patients with behavioral symptoms of dementia such as agitation
• Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo, and also have an increased risk of cerebrovascular events
Children and Adolescents• Not recommended for use in children under age 6
• Children should be closely monitored when taking trifluoperazine
• Oral: initial 1 mg; increase gradually; maximum 15 mg/day except in older children with severe symptoms
• Intramuscular: 1 mg once or twice a day
• Generally consider second-line after atypical antipsychotics
Pregnancy• Effective June 30, 2015, the FDA requires changes to the content and format of pregnancy and lactation information in prescription drug labels, including the elimination of the pregnancy letter categories; the Pregnancy and Lactation Labeling Rule (PLLR or final rule) applies only to prescription drugs and will be phased in gradually for drugs approved on or after June 30, 2001
• Controlled studies have not been conducted in pregnant women
• There is a risk of abnormal muscle movements and withdrawal symptoms in newborns whose mothers took an antipsychotic during the third trimester; symptoms may include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, severe difficulty breathing, and difficulty feeding
• Reports of drug-induced parkinsonism, jaundice, hyperreflexia, hyporeflexia in infants whose mothers took a phenothiazine during pregnancy
• Trifluoperazine should only be used during pregnancy if clearly needed
• Psychotic symptoms may worsen during pregnancy and some form of treatment may be necessary
• Atypical antipsychotics may be preferable to conventional antipsychotics or anticonvulsant mood stabilizers if treatment is required during pregnancy
Breast Feeding• Some drug is found in mother’s breast milk
• Recommended either to discontinue drug or bottle feed
Based on data Published online by Cambridge University Press
Compiled by Dr. Jash Ajmera